Evidence map›Paper›PMID 32102539›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2020

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.

Amrallah A Mohammed, Fifi Mostafa Elsayed, Mohammed Algazar, Hayam E Rashed, Abeer Hussien Anter

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Genomic Alterations in Quadruple-Negative Breast Cancer Tumors.International journal of molecular sciences · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Cytotoxic Effect of YH239-EE and Its Enantiomer on MCF7 Cell Line.Asian Pacific journal of cancer prevention : APJCP · 2024
    Article
  12. Article
  13. Core Needle Biopsy Accuracy for Androgen Receptor Expression in Invasive Breast Cancer.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2023
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Amrallah A MohammedDepartment of Medical Oncology, Faculty of Medicine, Zagazig University, Egypt.
Fifi Mostafa ElsayedDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Suez Canal University, Egypt.
Mohammed AlgazarDepartment of General Surgery, Faculty of Medicine, Zagazig University, Egypt.
Hayam E RashedDepartment of Pathology, Faculty of Medicine, Zagazig University, Egypt.
Abeer Hussien AnterDepartment of Clinical Oncology and Nuclear Medicine, Mansoura University Egypt.
Zagazig University · EGSuez Canal University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is growing evidence that the response to chemotherapy may be affected by Androgen Receptor (AR) expression suggesting that triple-negative breast cancers (TNBC) AR+ and quadruple negative breast cancer (QNBC) subtypes may have different diseases behavior. METHODOLOGY: We retrospectively estimated the predictive value of the AR expression in stage II and stage III TNBC patients treated with neoadjuvant chemotherapy (NAC) and correlated with the rate of pathological response (pCR).

resultsOf 89 TNBC patients, 29 patients (32.6%) were TNBC AR+ and 60 patients (67.4) were QNBC. Most of the patients were less than 60 years old. Of note, approximately 62% in the QNBC group were less than 40 years old compared with 39 % in the TNBC AR+ group. The Ki-67 expression was higher in the QNBC in comparison with TNBC AR+ being 86.7% and 65.5%, respectively. QNBC subgroup showed higher rates of pCR compared with TNBC; 60% and 24%, respectively. Higher Ki-67 expression, higher grade, and lymph node involvement were statistically significantly correlated with the rate of pCR in the QNBC group (p=0.02, p=0.04, and p=0.03, respectively). In contrast, no significant association was observed between pCR and clinical-pathological features in the TNBC AR+ group.

conclusionOur results suggested that the AR expression in TNBC may be applied as a predictive marker for NAC. TNBC AR+ had a lower rate of pCR compared with QNBC, suggesting that this subtype may have a partial chemoresistance.

Indexed as

Neoadjuvant TherapyAdultAntineoplastic AgentsCarcinoma, Ductal, BreastFemaleHumansKi-67 AntigenLymph NodesMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm StagingPrognosisReceptors, AndrogenRetrospective StudiesTreatment OutcomeAntineoplastic AgentsAR protein, humanKi-67 AntigenMKI67 protein, humanReceptors, AndrogenNeoadjuvant chemotherapypathological responseQuadruple negative breast cancertriple negative breast cancer

Identifiers

PMID32102539
PMCPMC7332128
OpenAlexW3007743544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.